



iDD biotech is granted new Patents in the USA and in China about its Fc optimized MABs anti-CD19

Lyon, 1st June 2016. Two important MABs of iDD biotech have been granted new Patents abroad: in the USA for iDD002 (US Patent No. 9,120,856) and in China for iDD001 (WO 2012/010562). These two new patents will support the development of therapeutic MAB anti-CD19, with high killing activity against many CD19 positive B cell malignancies.

From its proprietary MAB library and by using its MAB design advanced platform (WO 2012/010602), iDD biotech has generated next generation, pro-apoptotic humanized, Fc optimized and afucosylated MABs to enhance antibody dependent cellular cytotoxicity (ADCC), with or without complement dependent cytotoxicity (CDC) activities, respectively iDD001 and iDD002. Their potent *in vitro* and *in vivo* activity against B-LAL have been demonstrated.

Commenting on this milestone, Claudine Vermot-Desroches, (CSO) mentioned: *“Targeting CD19 is a promising approach to treat B-cell malignancies and various autoimmune disorders. Importantly, these MABs mediated also significantly higher level of apoptosis compared to other anti-CD19 MABs. They also provide a key advantage with favourable pharmacokinetics compared to bispecific MAB. Furthermore, they can be easily produced with generic wild type CHO cells used as host cells.”*

Paul Michalet, iDD biotech CEO added: *“iDD001 and iDD002 MAB anti-CD19 are in the pre-clinical phase of development for which we have developed a well-advanced bioprocess and have gained evidence of robust results. Considering their cutting edge positioning, validated by two patents granted in a few months, we are confident on iDD biotech product development capabilities to pursue their clinical development. These projects demonstrate the strong expertise and high efficiency of our team. They offer a strong opportunity for value creation in our company”.*

About the CD19 therapeutic markets

Fc-engineered antibodies, bispecific antibodies, antibody drug conjugates and CAR-T therapies are the major drug classes contributing to the CD19 targeting therapeutic market. The anti-CD19 therapeutic market is estimated at USD 0.1 billion in 2016 and is expected to amount to around USD 0.6 billion by 2020. Considering its strong potential for efficiency, it should then expand rapidly to reach close to USD 12 billion by 2030, meaning an annualized growth rate of around 41% between 2016 – 2030 (Research Market Report 2016).

About iDD biotech

iDD biotech is a biopharmaceutical company focused on developing innovative products in targeted immunotherapy, based upon monoclonal antibodies, for the treatment of cancer, autoimmune diseases and inflammation. The company is aiming at reinforcing the therapeutic arsenal and the pipeline of pharmaceutical companies.

iDD biotech owns key assets for its development: an extensive library of monoclonal antibodies with new potential targets, a portfolio of projects and patents, and several drug candidates.

With its technology platforms the company carries out the early stages of target validation and molecular and genetic engineering. It also produces antibodies for preclinical development. Strong intellectual property is a significant component of these activities.

In particular, iDD biotech has developed an innovative combination in biotherapy, in anti DR5 antibody, which led to the signature of an agreement with the biotechnology company Genmab, in March 2015. A first contractual milestone was achieved in April 2016 with the choice of the clinical candidate.

Based in Lyon since its inception, iDD biotech is a member of Lyonbiopole, a world competitiveness healthcare cluster based in Rhône-Alpes (France), where it has developed close relationships with academic research institutes and world renowned clinicians. iDD biotech is recognized as a key member of the industrial cluster in therapeutic antibodies.

For more information, www.idd-biotech.com

Contacts:

Delphine Peyrat-Stricker
Image Sept
+33 1 53 70 74 14
dpeyratstricker@image7.fr

Laurent Poinot
Image Sept
+33 1 53 70 74 77
lpoinot@image7.fr